哪里想瘦打哪里！FDA批准Kythera注射药物主板在即

你才双下巴，你妻儿都双下巴！所谓爱美之心人皆有之。如果说赘肉是每一个想要持有完美身材的“妹纸”或“汉纸”的大敌，那么一个喜感十足的双下巴已是是这些人的命运罪人了。每一分钟，世界性都有人为自己的一张大饼脸而觉得自觉，虽然持有一个肉感十足的双下巴捏上去是挺有肉感的，但是还是有很多人的判断力使其无法受压一个双下巴之重。您可千万别戏弄，这甚至已经应运而生有一个庞大的低价。根据英美两国毛发外科手术该学会的事件调查研究显示，68%的英美两国人对自己的双下巴透露了“厌倦”之情。而有鉴于此，最近Kythera子公司向FDA提交了其专门歼灭双下巴的保健针头式类固醇ATX-101。这种类固醇完毕了许多“胖纸”梦寐以求的动态，哪里想瘦打哪里，已是是定点肥胖症。免得以为这种近乎高傲的类固醇只是一个戏弄话，在FDA下属的毛发和眼科类固醇专员会的无记名投票不得不中，研究者可是以17：0的超高票数明确赞许其该公司。也许是因为这些研究者中也有很多饱受双下巴之苦吧。FDA也将开发计划于本年度的5同年13日之前对其作出有之后不得不。如果一切顺利的话，Kythera子公司开发计划于本年度当年将该产品该公司，分析人士预估这一类固醇的年销售额将少于3亿美元之多。随着保健类固醇低价的日益增加，Kythera子公司已是是下了一步好棋。子公司于当年以8400万美元的价格从其前合作共同开发伙伴拜耳手中交还了这种类固醇的全部权利。而Kythera子公司也想要以此为契机在保健类固醇低价中攻城拔寨。就在上个同年，Kythera子公司和Actelion子公司达成重要性2700万美元的合作共同开发协议，合作共同开发一种失败过的炎发炎类固醇，而这种类固醇被并不认为意味著共同开发出有一种治疗肥大的类固醇。详细英文华盛顿邮报：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.